Clinical Research Studies

If you have been diagnosed with relapsed and refractory mantle cell and/or low grade non-hodgkin lymphoma, you may qualify for a clinical trial studying the efficacy of bortezomib and rituximab in combination with MLN8237. Purpose: The goal of the study is to determine the recommended phase II dose of MLN8237 and bortezomib when combined with rituximab in patients with relapsed/refractory mantle cell and B-cell low grade non-Hodgkin lymphoma. The study will also determine the rate of overall response - complete response (disappearance of all signs of cancer in response to treatment) and partial response - (decrease in extent of cancer or size of tumor in response to treatment) for this group of subjects treated with the combination of MLN8237 plus bortezomib and rituximab.